Regulatory T cells move in when gliomas say "I Do".
Indoleamine 2,3-dioxygenase (IDO) is an enzyme with known immunosuppressive and tolerogenic effects in cancer. Mounting evidence has associated IDO expression with the induction of regulatory T cells (Treg) and malignant progression. IDO inhibition may therefore provide a promising therapeutic approach for glioblastoma, where the need for novel treatment is great.
Duke Brain Tumor Immunotherapy Program, Preston Robert Tisch Brain Tumor Center, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Bryan D
BD
Choi
Peter E
PE
Fecci
John H
JH
Sampson
D000818:Animals; D001932:Brain Neoplasms / Q000201:enzymology*; D005909:Glioblastoma / Q000201:enzymology*; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000378:metabolism*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase